InnoPharmax Inc (4172) Fair Value & Analysis
Healthcare · TW · Market cap 1.4B TWD
Fair value as of: Jun 24, 2026
Analysis
InnoPharmax Inc (4172) currently trades at 11.55 TWD, while our model-based Fair Value estimate is 10.52 TWD — implying the stock looks roughly 8.9% overvalued today. We read business quality at 95/100 (high quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: low).
About the company
InnoPharmax Inc., a specialty pharmaceutical company, develops and commercializes products for the treatment of oncology and other specialties in Taiwan. The company offers Imipenem and Cilastatin sodium solution under the Bestnem brand for the treatment of infections caused by susceptible organisms, such as lower respiratory tract, skin and skin structure, intra-abdominal, gynecologic, bone, and joint infections; contrast agents, such as gadopentetate dimeglumine under the Gadomni brand; oncology agents comprising bendamustine under the Innomustine brand; immunological agents under the Immurin brand; and Inpheno tablets for rare diseases. It also provides active pharmaceutical ingredient, including orphan drug and MRI enhancing agents. In addition, the company's product pipeline comprises D07001, which is in initiated phase II trial for treatment of pancreatic and lung cancer, as well as in phase III clinical trial to treat biliary tract cancer; D0191801, which is in preclinical tr…
Open the full interactive analysis →
Similar stocks
Frequently asked questions
Is InnoPharmax Inc (4172) undervalued?
What is the fair value of 4172?
What is the quality score of 4172?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.
Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.